<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070364</url>
  </required_header>
  <id_info>
    <org_study_id>EIG-LMD-002</org_study_id>
    <nct_id>NCT05070364</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV</brief_title>
  <acronym>LIMT-2</acronym>
  <official_title>Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eiger BioPharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 3 LIMT-2 study will evaluate the safety and efficacy of Peginterferon Lambda&#xD;
      treatment for 48 weeks with 24 weeks follow-up compared to no treatment for 12 weeks in&#xD;
      patients chronically infected with HDV. The primary analysis will compare the proportion of&#xD;
      patients with HDV RNA &lt; LLOQ at the 24-week post-treatment visit in the Peginterferon Lambda&#xD;
      treatment group vs the proportion of patients with HDV RNA &lt; LLOQ at the Week 12 visit in the&#xD;
      no-treatment comparator group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, parallel arm study that will allocate patients (2:1) with&#xD;
      chronic HDV infection to one of two treatment groups: Peginterferon Lambda 180 mcg QW for 48&#xD;
      weeks with 24 weeks follow-up (Arm 1, n=100), or no treatment for 12 weeks followed by&#xD;
      Peginterferon Lambda treatment for 48 weeks with 24 weeks of follow-up (Arm 2, n=50). All&#xD;
      patients will receive concomitant therapy with a potent 2nd generation anti-HBV nucleos(t)ide&#xD;
      analogue (NUC) throughout the study duration.&#xD;
&#xD;
      Data collected during Peginterferon Lambda treatment in Arm 2 will not be included in the&#xD;
      primary analysis. The primary purpose of Arm 2 is to provide benchmark data in a parallel&#xD;
      reference group for the expected rate of HDV RNA suppression among patients with chronic HDV&#xD;
      infection who receive 12 weeks of anti-HBV NUC therapy alone.&#xD;
&#xD;
      Prior to randomization, all patients will enter a run-in phase with 12 weeks of anti-HBV NUC&#xD;
      therapy, which will ensure virologic control of HBV (&lt; 100 IU/mL) prior to randomization and&#xD;
      start of Peginterferon Lambda therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Durable Virologic Response</measure>
    <time_frame>72 weeks</time_frame>
    <description>HDV RNA below the limit of quantitation at 24 weeks post-treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis Delta Virus</condition>
  <arm_group>
    <arm_group_label>Peginterferon Lambda for 48 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment for 12 weeks</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Lambda-1a</intervention_name>
    <description>Immunomodulator</description>
    <arm_group_label>Peginterferon Lambda for 48 weeks</arm_group_label>
    <other_name>Lambda</other_name>
    <other_name>Peginterferon Lambda</other_name>
    <other_name>Pegylated Interferon Lambda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic HDV infection documented by a positive HDV antibody test or a positive HDV RNA&#xD;
             by RT PCR test for at least 6 months prior to Screening&#xD;
&#xD;
          -  Quantifiable HDV RNA by RT-PCR test at Screening&#xD;
&#xD;
          -  Documented confirmed suppression of HBV DNA (&lt; 100 IU/mL) following at least 12 weeks&#xD;
             of anti-HBV NUC treatment with ETV or a TNF-based NUC (TDF or TAF)&#xD;
&#xD;
          -  Serum ALT &gt; upper limit of normal (ULN) and &lt; 10 × ULN.&#xD;
&#xD;
          -  Patients categorized with Child-Turcotte-Pugh score of ≤ 5 with well compensated liver&#xD;
             disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current evidence of decompensated liver disease (episodes of variceal&#xD;
             bleeding, ascites or encephalopathy)&#xD;
&#xD;
          -  Treatment with interferons (IFNs) or immunomodulators within 12 months of&#xD;
             randomization or refractory to prior IFN treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Ramza, MBA</last_name>
    <phone>650-272-6138</phone>
    <email>LIMT2@eigerbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Gangal, MSc</last_name>
    <phone>650-272-6138</phone>
    <email>LIMT2@eigerbio.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDV</keyword>
  <keyword>Hepatitis D</keyword>
  <keyword>Viral Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

